# A Study to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single and Multiple Doses of RO7049389 in Healthy Volunteers and Chronic Hepatitis B Virus (HBV) Infected Participants

> **NCT02952924** · PHASE1 · COMPLETED · sponsor: **Hoffmann-La Roche** · enrollment: 192 (actual)

## Conditions studied

- Hepatitis B, Chronic

## Interventions

- **DRUG:** Midazolam
- **OTHER:** Placebo
- **DRUG:** RO7049389

## Key facts

- **NCT ID:** NCT02952924
- **Lead sponsor:** Hoffmann-La Roche
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-12-14
- **Primary completion:** 2022-03-16
- **Final completion:** 2022-03-16
- **Target enrollment:** 192 (ACTUAL)
- **Last updated:** 2024-10-31


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02952924

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02952924, "A Study to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single and Multiple Doses of RO7049389 in Healthy Volunteers and Chronic Hepatitis B Virus (HBV) Infected Participants". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT02952924. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*